Search results
Showing 1 to 10 of 10 results for methylphenidate
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)
Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.
View recommendations for IPG748Show all sections
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.
February 2012 TA098 Attention deficit hyperactivity disorder - Methylphenidate, atomoxetine and dexamfetamine (review) 25 September 2005...
This quality standard covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in adults, young people and children (aged 3 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS39Show all sections
Sections for QS39
- Quality statements
- Quality statement 1: Confirmation of diagnosis
- Quality statement 2: Identification and referral in adults
- Quality statement 3: Continuity of child to adult services
- Quality statement 4: Parent training programmes
- Quality statement 5: Psychological treatments for children and young people
- Quality statement 6: Starting drug treatment
- Quality statement 7: Annual review of drug treatment
anabolic steroids), and those used to increase cognitive ability (such as methylphenidate). People using these drugs may not identify...
This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].
This guidance has been updated and replaced by NICE guideline NG87.
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.